Analysts Offer Insights on Healthcare Companies: NexGel Inc (NXGL), Taysha Gene Therapies (TSHA) and Durect (DRRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NexGel Inc (NXGL – Research Report), Taysha Gene Therapies (TSHA – Research Report) and Durect (DRRX – Research Report).

NexGel Inc (NXGL)

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on NexGel Inc, with a price target of $6.00. The company’s shares closed last Tuesday at $1.79.

According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.2% and a 27.3% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Virpax Pharmaceuticals, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NexGel Inc with a $6.00 average price target.

See today’s best-performing stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NXGL:

• Is NXGL a Buy, Before Earnings?
• NexGel enters supply agreement with AbbVie
• NEXGEL to Participate in the LD Micro Main Event XVI on October 3rd